

Jenette Creaney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6889329/publications.pdf>

Version: 2024-02-01

90
papers

4,660
citations

147801

31
h-index

102487

66
g-index

93
all docs

93
docs citations

93
times ranked

4537
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology. <i>Cytopathology</i> , 2022, 33, 84-92.	0.7	4
2	Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology. <i>Cancer Cytopathology</i> , 2022, , .	2.4	3
3	What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. <i>OncoImmunology</i> , 2022, 11, 2038403.	4.6	7
4	How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 858557.	3.5	4
5	BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 921-930.	1.1	23
6	Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2022, 14, .	8.2	24
7	Hyaluronic acid in viscous malignant mesothelioma pleural effusion. <i>Respirology Case Reports</i> , 2021, 9, e00694.	0.6	3
8	Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy. <i>Respirology</i> , 2021, 26, 138-139.	2.3	0
9	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 465-474.	2.4	1
10	Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2021, 84, 475-483.	2.3	1
11	Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. <i>PLoS ONE</i> , 2021, 16, e0250628.	2.5	4
12	Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3249-3258.	4.2	14
13	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1 tyrosine kinase inhibitor anticancer therapy. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 579-590.	2.6	7
14	The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 922-932.	1.1	19
15	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	30
16	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2020, 140, 87-92.	2.0	21
17	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. <i>OncoImmunology</i> , 2020, 9, 1684713.	4.6	12
18	Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1973-1982.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome. <i>American Journal of Dermatopathology</i> , 2020, 42, 872-875.	0.6	3
20	Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000551.	3.0	4
21	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. <i>OncImmunity</i> , 2020, 9, 1684714.	4.6	12
22	MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. <i>Disease Markers</i> , 2019, 2019, 1-9.	1.3	20
23	Malignant Pleural Mesothelioma: an Update for Pulmonologists. <i>Current Pulmonology Reports</i> , 2019, 8, 40-49.	1.3	4
24	Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions. <i>Respiration</i> , 2019, 98, 48-54.	2.6	9
25	Advances in pathological diagnosis of mesothelioma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 354-361.	2.6	12
26	Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 181-192.	2.5	13
27	Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. <i>Lung Cancer</i> , 2018, 119, 64-70.	2.0	23
28	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. <i>BMC Research Notes</i> , 2018, 11, 864.	1.4	7
29	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	9.4	422
30	Autoimmune antibodies and asbestos exposure: Evidence from Wittenoom, Western Australia. <i>American Journal of Industrial Medicine</i> , 2018, 61, 615-620.	2.1	8
31	Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. <i>PLoS ONE</i> , 2018, 13, e0190264.	2.5	57
32	Transient Treg depletion enhances therapeutic anti-cancer vaccination. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 16-28.	2.7	33
33	Malignant Mesothelioma Biomarkers. <i>Chest</i> , 2017, 152, 143-149.	0.8	72
34	Calretinin as a blood-based biomarker for mesothelioma. <i>BMC Cancer</i> , 2017, 17, 386.	2.6	34
35	Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. <i>BMC Cancer</i> , 2017, 17, 396.	2.6	30
36	Immunotherapy for Lung Malignancies. <i>Chest</i> , 2017, 151, 891-897.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Malignant pleural fluid from mesothelioma has potent biological activities. <i>Respirology</i> , 2017, 22, 192-199.	2.3	27
38	A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 103-118.	2.0	34
39	Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1003-1004.	3.2	3
40	Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. <i>Scientific Reports</i> , 2016, 6, 32643.	3.3	85
41	Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. <i>Biomarkers</i> , 2016, 21, 551-561.	1.9	5
42	Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. <i>BMJ Open</i> , 2016, 6, e011480.	1.9	16
43	ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 10 years in advance of clinical symptoms. <i>Clinical Proteomics</i> , 2016, 13, 2.	2.1	20
44	BAP1 mutations in mesothelioma: advances and controversies. <i>Current Pulmonology Reports</i> , 2016, 5, 13-19.	1.3	0
45	Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. <i>Chest</i> , 2016, 149, 1494-1500.	0.8	25
46	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 573-582.	1.1	126
47	Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. <i>BMC Cancer</i> , 2015, 15, 983.	2.6	13
48	Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>Diagnostic Cytopathology</i> , 2015, 43, 563-576.	1.0	34
49	Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 352-356.	2.6	26
50	Discovery of new biomarkers for malignant mesothelioma. <i>Current Pulmonology Reports</i> , 2015, 4, 15-21.	1.3	27
51	Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. <i>Thorax</i> , 2015, 70, 374-375.	5.6	0
52	Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma. <i>Acta Cytologica</i> , 2015, 59, 2-16.	1.3	71
53	Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. <i>Gene</i> , 2015, 563, 103-105.	2.2	27
54	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Oncolimmunology</i> , 2015, 4, e1011492.	4.6	26

#	ARTICLE	IF	CITATIONS
55	Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis. <i>Oncotarget</i> , 2015, 6, 1519-1530.	1.8	25
56	Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>CytoJournal</i> , 2015, 12, 26.	1.7	57
57	Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma. <i>Disease Markers</i> , 2014, 2014, 1-10.	1.3	24
58	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. <i>Thorax</i> , 2014, 69, 895-902.	5.6	128
59	A genome-wide association study for malignant mesothelioma risk. <i>Lung Cancer</i> , 2013, 82, 1-8.	2.0	45
60	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	2.0	51
61	Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?. <i>Lung Cancer</i> , 2013, 80, 39-44.	2.0	5
62	Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. <i>Lung Cancer</i> , 2013, 82, 491-498.	2.0	61
63	Comparison of the Diagnostic Accuracy of the <i>MSLN</i> Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum. <i>Disease Markers</i> , 2013, 35, 119-127.	1.3	31
64	A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. <i>Pathology</i> , 2013, 45, 44-48.	0.6	97
65	Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e61253.	2.5	71
66	Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells. <i>PLoS ONE</i> , 2013, 8, e63873.	2.5	10
67	The continual search for ideal biomarkers for mesothelioma: the hurdles. <i>Journal of Thoracic Disease</i> , 2013, 5, 364-6.	1.4	4
68	Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1541-1549.	1.6	199
69	A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1449-1456.	1.1	89
70	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1184-1191.	1.1	115
71	Association of Biomarker Levels with Severity of Asbestos-Related Diseases. <i>Safety and Health at Work</i> , 2012, 3, 17-21.	0.6	10
72	The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. <i>Nature Genetics</i> , 2011, 43, 668-672.	21.4	617

#	ARTICLE	IF	CITATIONS
73	Mesothelin and kidney function—Analysis of relationship and implications for mesothelioma screening. <i>Lung Cancer</i> , 2011, 73, 320-324.	2.0	27
74	Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma—Which is best?. <i>Lung Cancer</i> , 2011, 74, 55-60.	2.0	48
75	Auto-Antibodies to β -F1-ATPase and Vimentin in Malignant Mesothelioma. <i>PLoS ONE</i> , 2011, 6, e26515.	2.5	16
76	Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden. <i>Clinical Cancer Research</i> , 2011, 17, 1181-1189.	7.0	101
77	Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1461-1466.	1.1	15
78	Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2238-2246.	2.5	72
79	Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 869-74.	2.3	26
80	Serum and pleural fluid biomarkers for mesothelioma. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 366-370.	2.6	48
81	Soluble Mesothelin-related Protein in an Asbestos-exposed Population. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 832-837.	5.6	105
82	Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 851-857.	1.1	109
83	Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. <i>Thorax</i> , 2007, 62, 569-576.	5.6	106
84	Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma. <i>Chest</i> , 2007, 132, 1239-1246.	0.8	79
85	A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions. <i>Clinical Cancer Research</i> , 2006, 12, 5129-5135.	7.0	46
86	Soluble mesothelin related protein in mesothelioma. <i>Journal of Thoracic Oncology</i> , 2006, 1, 172-4.	1.1	7
87	Detection of Malignant Mesothelioma in Asbestos-Exposed Individuals: The Potential Role of Soluble Mesothelin-Related Protein. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 1025-1040.	2.2	31
88	Mesothelin-family proteins and diagnosis of mesothelioma. <i>Lancet</i> , The, 2003, 362, 1612-1616.	18.7	516
89	The BLM helicase is necessary for normal DNA double-strand break repair. <i>Cancer Research</i> , 2002, 62, 2766-70.	0.9	50
90	The Bloom's Syndrome Protein (BLM) Interacts with MLH1 but Is Not Required for DNA Mismatch Repair. <i>Journal of Biological Chemistry</i> , 2001, 276, 30031-30035.	3.4	91